Deucravacitinib
- Generic Name
- Deucravacitinib
- Brand Names
- Sotyktu
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O3
- CAS Number
- 1609392-27-9
- Unique Ingredient Identifier
- N0A21N6RAU
- Background
Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target. This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered cholesterol and triglyceride levels and liver and kidney dysfunction.
Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis. It was later approved by Health Canada in November 2022 and by the European Medicines Agency in March 2023.
- Indication
Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects
- Conditions
- Systemic Lupus ErythematosusHealthy Participants
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 84
- Registration Number
- NCT03541564
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 54
- Registration Number
- NCT03419910
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients
- Conditions
- LupusPsoriatic Arthritis
- Interventions
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT03402087
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients
- Conditions
- Systemic Lupus ErythematosusPsoriasisInflammatory Bowel DiseasesArthritic Psoriasis
- Interventions
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT03262727
- Locations
- 🇺🇸
Miami Research Associates, Miami, Florida, United States
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
- Conditions
- Inflammatory Bowel DiseasesSystemic Lupus ErythematosusArthritic PsoriasisPsoriasis
- Interventions
- Drug: BMS-986165 Capsule
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT03254784
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 363
- Registration Number
- NCT03252587
- Locations
- 🇺🇸
Local Institution - 0022, Decatur, Georgia, United States
🇺🇸Local Institution - 0023, El Cajon, California, United States
🇺🇸Little Rock Diagnostic Clinic, Little Rock, Arkansas, United States
Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin
- Conditions
- Inflammatory DiseasesAutoimmune Diseases
- Interventions
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT03044873
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT03004768
- Locations
- 🇺🇸
Covance Madison Clinical Research Unit, Madison, Wisconsin, United States
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 268
- Registration Number
- NCT02931838
- Locations
- 🇺🇸
Renstar Medical Research, Ocala, Florida, United States
🇺🇸NorthShore University Health System, Skokie, Illinois, United States
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2015-08-27
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 140
- Registration Number
- NCT02534636
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.